Clinical implications of neuroendocrine differentiation in prostate cancer

被引：71

作者：

Nelson, E. C. ^{[1
]}

Cambio, A. J. ^{[1
]}

Yang, J. C. ^{[1
]}

Ok, J-H ^{[1
]}

Lara, P. N., Jr. ^{[1
]}

Evans, C. P. ^{[1
]}

机构：

[1] Univ Calif Davis, Med Ctr, Dept Urol, Sacramento, CA 95817 USA

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2007年 / 10卷 / 01期

关键词：

androgen-independent prostate cancer; hormone refractory; neuroendocrine cells; neuroendocrine differentiation;

D O I：

10.1038/sj.pcan.4500922

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The cellular signaling pathways of the prostate play a central role in the induction, maintenance, and progression of prostate cancer (CaP). Neuroendocrine ( NE) cells demonstrate attributes that suggest they are an integral part of these signaling cascades. We summarize what is known regarding NE cells in CaP focusing on NE cellular transdifferentiation. This significant event in CaP progression appears to be accelerated by androgen deprivation ( AD) treatment. We examine biochemical pathways that may impact NE differentiation in a chronological manner focusing on AD therapy ( ADT) as a central event in inducing androgen-independent CaP. Our analysis is limited to the common adenocarcinoma pattern of CaP and excludes small-cell and carcinoid prostatic variants. In conclusion, we speculate on the future of treatment and research in this area.

引用

页码：6 / 14

页数：9

共 113 条

[31] Circulating chromogranin A and hormone refractory prostate cancer chemotherapy [J].

Cabrespine, A ;

Guy, L ;

Gachon, F ;

Curé, H ;

Chollet, P ;

Bay, JO .

JOURNAL OF UROLOGY, 2006, 175 (04) :1347-1352

[32] Vascular endothelial growth factor and signaling in the prostate:: more than angiogenesis [J].

Chevalier, S ;

Defoy, I ;

Lacoste, J ;

Hamel, L ;

Guy, L ;

Bégin, LR ;

Aprikian, AG .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 189 (1-2) :169-179

[33]

COHEN RJ, 1992, ARCH PATHOL LAB MED, V116, P65

[34] Prostatic hyperplasia:: An unknown feature of acromegaly [J].

Colao, A ;

Marzullo, P ;

Ferone, D ;

Spiezia, S ;

Cerbone, G ;

Marinò, V ;

Di Sarno, A ;

Merola, B ;

Lombardi, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :775-779

[35]

Cox ME, 1999, CANCER RES, V59, P3821

[36]

Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO

[37]

2-C

[38] Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma [J].

Cussenot, O ;

Villette, JM ;

Valeri, A ;

Cariou, G ;

Desgrandchamps, F ;

Cortesse, A ;

Meria, P ;

Teillac, P ;

Fiet, J ;

LeDuc, A .

JOURNAL OF UROLOGY, 1996, 155 (04) :1340-1343

[39] Interleukin-6-and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells [J].

Deeble, PD ;

Murphy, DJ ;

Parsons, SJ ;

Cox, ME .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (24) :8471-8482

[40]

Diaz M, 1998, PROSTATE, P32

← 1 2 3 4 5 6 7 8 9 10 →